Heart failure & cardiomyopathies
Effect of 2022 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) Criteria on Stages of Heart Failure in a Pooled Community Cohort
An erratum to this article was published (J Am Coll Cardiol, 5 Sep 2023 ↗)
Authors' conclusion
New standards for HF staging resulted in a substantial shift of community-based individuals from stage A to stage B. Those with stage B HF in the new system were at high risk for progression to symptomatic HF.
Study context
- Population
- Community-based participants of MESA, CHS and FHS
- Participants
- 11,618 participants
- Comparison
- 2022 vs 2013 ACC/AHA/HFSA heart failure (HF) staging criteria
- Healthyn = 1,943
- Stage An = 4,348
- Stage Bn = 5,019
- Stage C/Dn = 308
- Outcome
- Prevalence and prognosis of HF stages by 2013 vs 2022 ACC/AHA/HFSA definitions
Methodological detailsMESA, CHS and FHS cohorts
- MESA, CHS and FHS cohorts
Pooled result
As reported in the abstract
Prevalence of HF stages (2022 staging)
- Stage B proportion, 2013 vs 2022 criteria
- increase from 15.9% to 43.2%
Further pooled results
Progression to symptomatic HF, stage B (2022 criteria)
| HR (95% CI) | P value | ||
|---|---|---|---|
| Stage B | 10.61 (9.00–12.51) | P < 0.001 | |
| 0.050.21520Hazard ratio (log scale) |
- Progression to symptomatic HF, stage B (2022 criteria): relative risk remained similar despite more individuals designated stage B
Original publication
Effect of 2022 ACC/AHA/HFSA Criteria on Stages of Heart Failure in a Pooled Community Cohort. J Am Coll Cardiol. Published 13 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →